Shots:
- Sanofi has reported the P-II (ElevAATe) trial data assessing efdoralprin alfa (Q3W or Q4W) vs SoC plasma-derived augmentation therapy (QW) in 97 adults with AATD emphysema for ~32wks.
- Trial met its 1EP with a greater mean increase in functional AAT (fAAT) levels at Wk. 32 & achieved key 2EPs of higher fAAT levels & higher % of days above the lower limit of the normal range for both dosing; data to be presented in future meetings
- Efdoralprin alfa will be further evaluated in the P-II (ElevAATe OLE) study to assess its safety & Sanofi plans to engage global regulatory authorities to determine further development steps
Ref: Sanofi | Image: Sanofi | Press Release
Related News:- Sanofi’s Wayrilz (Rilzabrutinib) Receives the CHMP’s Positive Opinion to Treat Immune Thrombocytopenia (ITP)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
